1
|
Magalingam KB, Somanath SD, Haleagrahara N, Selvaduray KR, Radhakrishnan AK. Unravelling the neuroprotective mechanisms of carotenes in differentiated human neural cells: Biochemical and proteomic approaches. Food Chem (Oxf) 2022; 4:100088. [PMID: 35415676 DOI: 10.1016/j.fochms.2022.100088] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Revised: 02/08/2022] [Accepted: 02/11/2022] [Indexed: 12/20/2022]
Abstract
Total mixed carotenes (TMC) protect differentiated human neural cells against 6-hydroxydopamine-induced toxicity. TMC elevated the antioxidant enzymes activities and suppressed generation of reactive oxygen species. TMC augmented the dopamine and tyrosine hydroxylase levels. TMC exerted differential protein expression in human neural cells.
Carotenoids, fat-soluble pigments found ubiquitously in plants and fruits, have been reported to exert significant neuroprotective effects against free radicals. However, the neuroprotective effects of total mixed carotenes complex (TMC) derived from virgin crude palm oil have not been studied extensively. Therefore, the present study was designed to establish the neuroprotective role of TMC on differentiated human neural cells against 6-hydroxydopamine (6-OHDA)-induced cytotoxicity. The human neural cells were differentiated using retinoic acid for six days. Then, the differentiated neural cells were pre-treated for 24 hr with TMC before exposure to 6-OHDA. TMC pre-treated neurons showed significant alleviation of 6-OHDA-induced cytotoxicity as evidenced by enhanced activity of the superoxide dismutase (SOD) and catalase (CAT) enzymes. Furthermore, TMC elevated the levels of intra-neuronal dopamine and tyrosine hydroxylase (TH) in differentiated neural cells. The 6-OHDA induced overexpression of α-synuclein was significantly hindered in neural cells pre-treated with TMC. In proteomic analysis, TMC altered the expression of ribosomal proteins, α/β isotypes of tubulins, protein disulphide isomerases (PDI) and heat shock proteins (HSP) in differentiated human neural cells. The natural palm phytonutrient TMC is a potent antioxidant with significant neuroprotective effects against free radical-induced oxidative stress.
Collapse
Key Words
- 6-OHDA, 6-hydroxydopamine
- 6-hydroxydopamine
- AD, Alzheimer’s disease
- BCM, beta-carotene-15,15′-monooxygenase
- CAT, catalase
- DRD2, dopamine receptor D2
- Dopamine
- ER, endoplasmic reticulum
- GO, gene ontology
- HSP, Heat shock protein
- HSPA9, Heat shock protein family A (HSP70) member 9
- HSPD1, Heat shock protein family D (HSP60) member 1
- KEGG, Kyoto Encyclopedia of Genes and Genomes
- LC-MS/MS, liquid chromatography-double mass spectrometry
- LDH, lactate dehydrogenase
- MCODE, minimal common oncology data elements
- MS, mass spectrometry
- Mixed carotene
- PD, Parkinson's disease
- PDI, protein disulphide isomerases
- PHB2, prohibitin 2
- PPI, protein–protein interaction
- RAN, Ras-related nuclear protein
- ROS, reactive oxygen species
- RPs, ribosomal proteins
- SH-SY5Y neuroblastoma cells
- SOD, superoxide dismutase
- TH, tyrosine hydroxylase
- TMC, total mixed carotene complex
Collapse
|
2
|
Shi W, Zemel D, Sridhar S, Mount RA, Richardson RM, Eden UT, Han X, Kramer MA, Chu CJ. Spike ripples in striatum correlate with seizure risk in two mouse models. Epilepsy Behav Rep 2022; 18:100529. [PMID: 35274094 DOI: 10.1016/j.ebr.2022.100529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Revised: 01/21/2022] [Accepted: 02/05/2022] [Indexed: 11/28/2022] Open
Abstract
Epilepsy biomarkers from electroencephalogram recordings are routinely used to assess seizure risk and localization. Two widely adopted biomarkers include: (i) interictal spikes, and (ii) high frequency ripple oscillations. The combination of these two biomarkers, ripples co-occurring with spikes (spike ripples), has been proposed as an improved biomarker for the epileptogenic zone and epileptogenicity in humans and rodent models. Whether spike ripples translate to predict seizure risk in rodent seizure models is unknown. Further, recent evidence suggests ictal networks can include deep gray nuclei in humans. Whether pathologic spike ripples and seizures are also observed in the basal ganglia in rodent models has not been explored. We addressed these questions using local field potential recordings from mice with and without striatal seizures after carbachol or 6-hydroxydopamine infusions into the striatum. We found increased spike ripples in the interictal and ictal periods in mice with seizures compared to pre-infusion and post-infusion seizure-free recordings. These data provide evidence of electrographic seizures involving the striatum in mice and support the candidacy of spike ripples as a translational biomarker for seizure risk in mouse models.
Collapse
|
3
|
Venkatesan D, Iyer M, Narayanasamy A, Siva K, Vellingiri B. Kynurenine pathway in Parkinson's disease-An update. eNeurologicalSci 2020; 21:100270. [PMID: 33134567 PMCID: PMC7585940 DOI: 10.1016/j.ensci.2020.100270] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Revised: 08/05/2020] [Accepted: 08/26/2020] [Indexed: 12/24/2022] Open
Abstract
Parkinson's disease (PD) is a complex multi-factorial neurodegenerative disorder where various altered metabolic pathways contribute to the progression of the disease. Tryptophan (TRP) is a major precursor in kynurenine pathway (KP) and it has been discussed in various in vitro studies that the metabolites quinolinic acid (QUIN) causes neurotoxicity and kynurenic acid (KYNA) acts as neuroprotectant respectively. More studies are also focused on the effects of other KP metabolites and its enzymes as it has an association with ageing and PD pathogenesis. Until now, very few studies have targeted the role of genetic mutations in abnormal KP metabolism in adverse conditions of PD. Therefore, the present review gives an updated research studies on KP in connection with PD. Moreover, the review emphasizes on the urge for the development of biomarkers and also this would be an initiative in generating an alternative therapeutic approach for PD.
Collapse
Key Words
- 3-HAA, 3-hydroxyanthranilic acid
- 3-HK, 3-hydroxykynurenine
- 6-OHDA, 6-hydroxydopamine
- AA, anthranilic acid
- ACMSD, amino-carboxymuconatesemialdehyde decarboxylase
- AD, Alzheimer's disease
- ATP, adenosine triphosphate
- Ageing
- AhR, aryl hydrocarbon receptor
- Biomarkers
- CNS, central nervous system
- CSF, cerebrospinal fluid
- DA, dopaminergic
- FAM, formamidase
- IDO-1, indoleamine-2,3-dioxygenases
- IFN-γ, interferon-γ
- KATs, kynurenine aminotransferases
- KMO, kynurenine −3-monooxygenase
- KP, Kynurenine pathway
- KYN, kynurenine
- KYNA, kynurenic acid
- Kynurenine pathway (KP)
- L-DOPA, L-dopamine
- LID, L-DOPA-induced dyskinesia
- MPTP, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
- NAD+, nicotinamide adenine dinucleotide
- NADPH, nicotinamide adenine dinucleotide phosphate
- NFK, N′-formylkynurenine
- NMDA, N-methyl-d-aspartate
- PA, picolinic acid
- PD, Parkinson's disease
- Parkinson's disease (PD)
- QUIN, quinolinic acid
- RBCs, red blood cells
- SNpc, substantianigra pars compacta
- TDO, tryptophan 2,3-dioxygenase
- TRP, tryptophan
- Therapeutics
- XA, xanthurenic acid
- ZNS, zonisamide
- α-synuclein, αSyn
Collapse
Affiliation(s)
- Dhivya Venkatesan
- Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore 641 046, Tamil Nadu, India
| | - Mahalaxmi Iyer
- Department of Zoology, Avinashilingam Institute for Home Science and Higher Education for Women, Coimbatore 641 043, Tamil Nadu, India
| | - Arul Narayanasamy
- Disease Proteomics Laboratory, Department of Zoology, Bharathiar University, Coimbatore 641 046, Tamil Nadu, India
| | - Kamalakannan Siva
- National Centre for Disease Control, Ministry of Health and Family Welfare, Government of India, New Delhi 110054, India
| | - Balachandar Vellingiri
- Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore 641 046, Tamil Nadu, India
| |
Collapse
|
4
|
Herat LY, Magno AL, Rudnicka C, Hricova J, Carnagarin R, Ward NC, Arcambal A, Kiuchi MG, Head GA, Schlaich MP, Matthews VB. SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection. JACC Basic Transl Sci 2020; 5:169-179. [PMID: 32140623 PMCID: PMC7046513 DOI: 10.1016/j.jacbts.2019.11.007] [Citation(s) in RCA: 130] [Impact Index Per Article: 32.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Revised: 11/19/2019] [Accepted: 11/19/2019] [Indexed: 02/09/2023]
Abstract
SGLT2 inhibitors improve cardiovascular outcomes. SGLT2 inhibitor–induced sympathetic nervous system inhibition may be an underlying mechanism. Chemical denervation in neurogenic hypertensive mice reduces renal SGLT2 expression. SGLT2 inhibition lowered blood pressure and resulted in significantly reduced tyrosine hydroxylase and norepinephrine levels in the kidney tissue of neurogenic hypertensive mice. Crosstalk between the sympathetic nervous system and SGLT2 regulation appears as a key mechanism of the cardiorenal protective effects demonstrated with SGLT2 inhibition.
Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic hypertensive Schlager (BPH/2J) mice reduced blood pressure, improved glucose homeostasis, and reduced renal SGLT2 protein expression. Inhibition of SGLT2 prevented weight gain, reduced blood pressure, significantly reduced elevations of tyrosine hydroxylase and norepinephrine, and protects against endothelial dysfunction. These findings provide evidence for significant crosstalk between activation of the sympathetic nervous system and SGLT2 regulation and possible ancillary effects on endothelial function, which may contribute to the observed cardiorenal protective effects of SGLT2 inhibition.
Collapse
Affiliation(s)
- Lakshini Y Herat
- Dobney Hypertension Centre, School of Biomedical Science, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia
| | - Aaron L Magno
- Research Centre, Royal Perth Hospital, Perth, Australia
| | | | - Jana Hricova
- Dobney Hypertension Centre, School of Biomedical Science, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia
| | - Revathy Carnagarin
- Dobney Hypertension Centre, School of Medicine, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia
| | - Natalie C Ward
- School of Medicine, Royal Perth Hospital, University of Western Australia, Perth, Australia.,School of Public Health, Curtin University, Perth, Australia.,Curtin Health Innovation Research Institute, Curtin University, Perth, Australia
| | - Angelique Arcambal
- School of Medicine, Royal Perth Hospital, University of Western Australia, Perth, Australia.,Université de La Réunion, Saint-Denis, Réunion, France
| | - Marcio G Kiuchi
- Dobney Hypertension Centre, School of Medicine, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia
| | - Geoff A Head
- Baker Heart and Diabetes Institute, Melbourne, Australia
| | - Markus P Schlaich
- Dobney Hypertension Centre, School of Medicine, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia.,Department of Cardiology and Department of Nephrology, Royal Perth Hospital, Perth, Australia
| | - Vance B Matthews
- Dobney Hypertension Centre, School of Biomedical Science, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia
| |
Collapse
|
5
|
Morimoto S, Takahashi S, Fukushima K, Saya H, Suzuki N, Aoki M, Okano H, Nakahara J. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Regen Ther 2019; 11:143-166. [PMID: 31384636 PMCID: PMC6661418 DOI: 10.1016/j.reth.2019.07.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Revised: 07/04/2019] [Accepted: 07/09/2019] [Indexed: 11/19/2022] Open
Abstract
Introduction Amyotrophic lateral sclerosis (ALS) is an intractable and incurable neurological disease. It is a progressive disease characterized by muscle atrophy and weakness caused by selective vulnerability of upper and lower motor neurons. In disease research, it has been common to use mouse models carrying mutations in responsible genes for familial ALS as pathological models of ALS. However, there is no model that has reproduced the actual conditions of human spinal cord pathology. Thus, we developed a method of producing human spinal motor neurons using human induced pluripotent stem cells (iPSCs) and an innovative experimental technique for drug screening. As a result, ropinirole hydrochloride was eventually discovered after considering such results as its preferable transitivity in the brain and tolerability, including possible adverse reactions. Therefore, we explore the safety, tolerability and efficacy of ropinirole hydrochloride as an ALS treatment in this clinical trial. Methods The ROPALS trial is a single-center double-blind randomized parallel group-controlled trial of the safety, tolerability, and efficacy of the ropinirole hydrochloride extended-release tablet (Requip CR) at 2- to 16-mg doses in patients with ALS. Twenty patients will be recruited for the active drug group (fifteen patients) and placebo group (five patients). All patients will be able to receive the standard ALS treatment of riluzole if not changed the dosage during this trial. The primary outcome will be safety and tolerability at 24 weeks, defined from the date of randomization. Secondary outcome will be the efficacy, including any change in the ALS Functional Rating Scale-Revised (ALSFRS-R), change in the Combined Assessment of Function and Survival (CAFS), and the composite endpoint as a sum of Z-transformed scores on various clinical items. Notably, we will perform an explorative search for a drug effect evaluation using the patient-derived iPSCs to prove this trial concept. Eligible patients will have El Escorial Possible, clinically possible and laboratory-supported, clinically probable, or clinically definite amyotrophic lateral sclerosis with disease duration less than 60 months (inclusive), an ALSFRS-R score ≥2 points on all items and age from 20 to 80 years. Conclusion Patient recruitment began in December 2018 and the last patient is expected to complete the trial protocol in November 2020. Trial registration Current controlled trials UMIN000034954 and JMA-IIA00397. Protocol version version 1.6 (Date; 5/Apr/2019).
Collapse
Key Words
- %FVC, Forced vital capacity
- 6-OHDA, 6-hydroxydopamine
- 8-OHdG, 8-Hydroxydeoxyguanosine
- ADR, Adverse reaction
- AE, Adverse effect
- ALP, Alkaline phosphatase
- ALS, Amyotrophic lateral sclerosis
- ALSAQ-40, Amyotrophic Lateral Sclerosis Assessment Questionnaire-40
- ALSFRS-R, ALS Functional Rating Scale-Revised
- ALT, Alanine aminotransferase
- APTT, Activated partial thromboplastin time
- AST, Aspartate aminotransferase
- Amyotrophic lateral sclerosis
- BUN, Blood urea nitrogen
- CAFS, Combined Assessment of Function and Survival
- CK, Creatine kinase
- CPK, Creatine phosphokinase
- CRP, C-reactive protein
- CTCAE, Common terminology Criteria for Adverse Events
- EDC, Electronic data capture
- FALS, Familial ALS
- FAS, Full analysis set
- GCP, Good clinical practice
- HBs, Hepatitis B surface
- HCG, Human chorionic gonadotropin
- HCV, Hepatitis C virus
- HDL, High-density lipoprotein
- HIV, Human immunodeficiency virus
- HTLV-1, Human T-cell leukemia virus type 1
- IRB, Institutional review board
- LDH, Lactate dehydrogenase
- LDL, Low-density lipoprotein
- MMT, Manual muscle testing
- NfL, Neurofilament light chain
- PPS, Per protocol set
- PT, Prothrombin time
- QOL, Quality of life
- Requip CR
- Ropinirole hydrochloride
- SAE, Severe adverse effect
- SALS, sporadic ALS
- SOD, Superoxide dismutase
- TDP-43, Transactive response DNA-binding protein 43
- TPHA, Treponema pallidum hemagglutination
- iPSC-drug discovery
Collapse
Affiliation(s)
- Satoru Morimoto
- Department of Physiology, Keio University School of Medicine, Japan
- Department of Neurology, Keio University School of Medicine, Japan
| | | | - Komei Fukushima
- Department of Physiology, Keio University School of Medicine, Japan
| | - Hideyuki Saya
- Division of Gene Regulation, Institute for Advanced Medical Research, Graduate School of Medicine, Keio University, Japan
| | - Norihiro Suzuki
- Department of Neurology, Keio University School of Medicine, Japan
- Department of Neurology, Shonan Keiiku Hospital, Japan
| | - Masashi Aoki
- Department of Neurology, Tohoku University, School of Medicine, Japan
| | - Hideyuki Okano
- Department of Physiology, Keio University School of Medicine, Japan
- Corresponding author. Keio University Graduate School of Medicine, Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. Fax: +81 3 3357 5445.
| | - Jin Nakahara
- Department of Neurology, Keio University School of Medicine, Japan
| |
Collapse
|
6
|
Rai SN, Dilnashin H, Birla H, Singh SS, Zahra W, Rathore AS, Singh BK, Singh SP. The Role of PI3K/Akt and ERK in Neurodegenerative Disorders. Neurotox Res 2019; 35:775-795. [PMID: 30707354 DOI: 10.1007/s12640-019-0003-y] [Citation(s) in RCA: 230] [Impact Index Per Article: 46.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Revised: 01/05/2019] [Accepted: 01/15/2019] [Indexed: 12/27/2022]
Abstract
Disruption of Akt and Erk-mediated signal transduction significantly contributes in the pathogenesis of various neurodegenerative diseases (NDs), such as Parkinson's disease, Alzheimer's diseases, Huntington's disease, and many others. These regulatory proteins serve as the regulator of cell survival, motility, transcription, metabolism, and progression of the cell cycle. Therefore, targeting Akt and Erk pathway has been proposed as a reasonable approach to suppress ND progression. This review has emphasized on involvement of Akt/Erk cascade in the neurodegeneration. Akt has been reported to regulate neuronal toxicity through its various substrates like FOXos, GSK3β, and caspase-9 etc. Akt is also involved with PI3K in signaling pathway to mediate neuronal survival. ERK is another kinase which also regulates proliferation, differentiation, and survival of the neural cell. There has also been much progress in developing a therapeutic molecule targeting Akt and Erk signaling. Therefore, improved understanding of the molecular mechanism behind the regulatory aspect of Akt and Erk networks can make strong impact on exploration of the neurodegenerative disease pathogenesis.
Collapse
Key Words
- 6-OHDA, 6-hydroxydopamine
- BDNF, brain-derived neurotrophic factor
- HD, Huntington disease
- MAPK, mitogen-activated protein-extracellular kinase
- MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- NDs, neurodegenerative disorders
- Nrf2, nuclear factor erythroid 2 p45-related factor 2
- PD, Parkinson’s disease
Collapse
Affiliation(s)
- Sachchida Nand Rai
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India
| | - Hagera Dilnashin
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India
| | - Hareram Birla
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India
| | - Saumitra Sen Singh
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India
| | - Walia Zahra
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India
| | - Aaina Singh Rathore
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India
| | - Brijesh Kumar Singh
- Department of Pathology and Cell Biology, Columbia University Medical Centre, Columbia University, New York, NY, 10032, USA
| | - Surya Pratap Singh
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, 221005, India.
| |
Collapse
|
7
|
Parga JA, Rodriguez-Perez AI, Garcia-Garrote M, Rodriguez-Pallares J, Labandeira-Garcia JL. Data on the effect of Angiotensin II and 6-hydroxydopamine on reactive oxygen species production, antioxidant gene expression and viability of different neuronal cell lines. Data Brief 2018; 21:934-42. [PMID: 30426047 DOI: 10.1016/j.dib.2018.10.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 10/15/2018] [Accepted: 10/22/2018] [Indexed: 11/21/2022] Open
Abstract
This article describes the effect of the oxidative stress inducers Angiotensin II and 6-hydroxydopamine (6-OHDA) on different cell lines. The levels of expression Angiotensin type 1 and type 2 receptors in different dopaminergic cell lines are shown. The data indicate that treatment with Angiotensin II and 6-OHDA increases the production of reactive oxygen species (ROS) and decreases cell viability. NRF2 is a transcription factor induced by ROS. We provide data that NRF2 overexpression increases cell viability in response to oxidative stress inducers compared to control cells, and that these inducers can, both separately and in combination, enhance the expression of NRF2-regulated genes heme oxygenase 1 (Hmox1), NAD(P)H quinone dehydrogenase 1 (Nqo1) and Kruppel like factor 9 (Klf9). Interpretation of these data and additional information is presented in the research article “Angiotensin II induces oxidative stress and upregulates neuroprotective signaling from the NRF2 and KLF9 pathway in dopaminergic cells“ (Parga et al., 2018) [1].
Collapse
Key Words
- 6-OHDA, 6-hydroxydopamine
- AT1, angiotensin type 1 receptor
- AT2, angiotensin type 2 receptor
- AngII, angiotensin II
- DCFDA, 2′,7′-dichlorofluorescin-diacetate
- Dopaminergic
- H2O2, hydrogen peroxide
- Hmox1, heme oxygenase 1
- KLF9
- KLF9, Kruppel like factor 9
- MTT, methylthiazolyldiphenyl-tetrazolium
- NAC, N-Acetyl-L-Cysteine
- NRF2
- NRF2, nuclear factor-E2-related factor 2
- Nqo1, NAD(P)H quinone dehydrogenase 1
- Oxidative stress
- ROS, reactive oxygen species
- Redox signaling
- Renin-angiotensin system
- pLV-KLF9, pLV-SV40-KLF9-puro
- pLV-empty, pLV-SV40-puro
Collapse
|
8
|
Giordano S, Darley-Usmar V, Zhang J. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. Redox Biol 2013; 2:82-90. [PMID: 24494187 PMCID: PMC3909266 DOI: 10.1016/j.redox.2013.12.013] [Citation(s) in RCA: 266] [Impact Index Per Article: 24.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2013] [Revised: 12/15/2013] [Accepted: 12/17/2013] [Indexed: 12/13/2022] Open
Abstract
Oxidative stress including DNA damage, increased lipid and protein oxidation, are important features of aging and neurodegeneration suggesting that endogenous antioxidant protective pathways are inadequate or overwhelmed. Importantly, oxidative protein damage contributes to age-dependent accumulation of dysfunctional mitochondria or protein aggregates. In addition, environmental toxins such as rotenone and paraquat, which are risk factors for the pathogenesis of neurodegenerative diseases, also promote protein oxidation. The obvious approach of supplementing the primary antioxidant systems designed to suppress the initiation of oxidative stress has been tested in animal models and positive results were obtained. However, these findings have not been effectively translated to treating human patients, and clinical trials for antioxidant therapies using radical scavenging molecules such as α-tocopherol, ascorbate and coenzyme Q have met with limited success, highlighting several limitations to this approach. These could include: (1) radical scavenging antioxidants cannot reverse established damage to proteins and organelles; (2) radical scavenging antioxidants are oxidant specific, and can only be effective if the specific mechanism for neurodegeneration involves the reactive species to which they are targeted and (3) since reactive species play an important role in physiological signaling, suppression of endogenous oxidants maybe deleterious. Therefore, alternative approaches that can circumvent these limitations are needed. While not previously considered an antioxidant system we propose that the autophagy-lysosomal activities, may serve this essential function in neurodegenerative diseases by removing damaged or dysfunctional proteins and organelles. Significant oxidative damage occurs in neurodegenerative disease brains. Effective in animal models with single toxins, antioxidants are ineffective in clinical trials. The failure of antioxidant therapy maybe due to propagation of cellular damage. Autophagic clearance of diverse damaged molecules may provide antioxidant mechanisms. Further mechanistic and translational studies on autophagy therapy are needed.
Collapse
Key Words
- 6-OHDA, 6-hydroxydopamine
- Animal models
- Anti-oxidants
- Autophagy
- CBZ, carbamazepine
- Clinical trials
- EGCG, epigallocatechin gallate
- GSH, glutathione
- HIF1α, hypoxia-inducible factor 1-alpha
- HNE, 4-hydroxynonenal
- LRRK2, leucine-rich repeat kinase 2
- MDA, malondialdehyde
- MPP+, 1-methyl-4-phenylpyridinium
- MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine
- MitoQ, mitochondrially-targeted coenzyme Q
- Mitochondrial dysfunction
- MnSOD, manganese superoxide dismutase
- Neurons
- Nrf2, Nuclear factor (erythroid-derived 2)-like 2
- PINK1, PTEN-induced putative kinase 1
- Parkinson’s disease
- Protein aggregation
- ROS/RNS, reactive oxygen and nitrogen species
- Reactive oxygen species
- Redox signaling
- SOD, superoxide dismutase
- Selegiline, N-propargyl-methamphetamine
- Sirt1, NAD-dependent deacetylast sirtuin-1
- TFEB, transcription factor EB
- Toxins
- UCHL1, ubiquitin carboxyl-terminal hydrolase L1
- UPDRS, Unified Parkinson’s Disease Rating Scale
- curcumin, (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
- iPSC, induced pluripotent stem cells
- rasagiline, N-propargyl-1-(R)-aminoindan
- the ADAGIO study, the Attenuation of Disease Progression with Azilect Given Once-daily) study
- the DATATOP Study, the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism Study
- the NET-PD network, the NINDS Exploratory Trials in Parkinson’s Disease (NET-PD) network
- the TEMPO Study, the TVP-1012 in Early Monotherapy for PD Outpatients Study
Collapse
Affiliation(s)
- Samantha Giordano
- Center for Free Radical Biology, University of Alabama at Birmingham, United States ; Department of Pathology, University of Alabama at Birmingham, United States
| | - Victor Darley-Usmar
- Center for Free Radical Biology, University of Alabama at Birmingham, United States ; Department of Pathology, University of Alabama at Birmingham, United States
| | - Jianhua Zhang
- Center for Free Radical Biology, University of Alabama at Birmingham, United States ; Department of Pathology, University of Alabama at Birmingham, United States ; Department of Veterans Affairs, Birmingham VA Medical Center, United States
| |
Collapse
|